cisplatin,pemetrexed,pembrolizumab,gemcitabine
merck
['key,note,62', 'keynote,671', 'nsclc', 'pembro', 'sclc', 'keynote-671']
#asco23
perioperative pembrolizumab for ensclc: keynote-671 neoadjuvant 4cycles pembro plus cht surgery 13 cycles pembro pcr: 18% vs 4% mpr: 30% vs 11% 2y efs: 62.4% vs 40.6% 2y os: 81.9% vs 77.6% 
Medical Oncologist.                                            
        
On the trail of #SCIENCE to turn cancer into a manageable chronic disease. #bcsm #crcsm